Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04930445 · ClinicalTrials.gov registry record
Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 265
- Enrollment target
NCT04930445: Clinical Trial study, sponsored by Pfizer.
NCT04930445 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 265 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04930445 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 265 participants
- Enrollment target
Study Summary
This registry is an observational study designed to evaluate the effect of Oxbryta in individuals with SCD in a real-world setting.
Primary Outcome
The pre-Oxbryta (baseline) value was the latest measurement on or prior to the first dose of Oxbryta. Post-Oxbryta value was the measurement for multiple assessments at the same specific visit, the average was used.
Interventions
- DRUG Oxbryta® (voxelotor) 500mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2022-02-04 |
| Est. Completion | 2024-10-10 |
Why NCT04930445 stopped before completion
NCT04930445 is an observational study that tracks outcomes without assigning an intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Oxbryta® (voxelotor) 500mg Tablets is the first listed.
NCT04930445 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04930445 about?
NCT04930445 is a clinical study titled "Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD". This registry is an observational study designed to evaluate the effect of Oxbryta in individuals with SCD in a real-world setting.
What is the current status of trial NCT04930445?
This trial is currently terminated. The enrollment target is 265 participants. The study started on 2022-02-04. Estimated completion is 2024-10-10.
What interventions are being tested in trial NCT04930445?
The interventions under investigation include: Oxbryta® (voxelotor) 500mg Tablets (DRUG).
Who is sponsoring clinical trial NCT04930445?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443126 · 265 participants · Phase 1
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
- NCT05470491 · 265 participants · Phase 1
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- NCT07301905 · 265 participants · NA
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
- NCT07470853 · 265 participants · Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI